Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: sitagliptin


Double‐blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin up‐titration in treatment of patients with type 2 diabetes: the CompoSIT‐M Study

January 6th 2019

In participants not at HbA1c goal on a sub‐maximal dose of metformin, addition of sitagliptin at the time of metformin dose up‐titration improved glycemic response and HbA1c goal attainment with similar safety and tolerability compared to metformin up‐titration alone (Diabetes, Obesity and Metabolism)

Categories: News, Treatment
Tags: HbA1c, metformin, sitagliptin

Categories: Treatment
Tags: HbA1c, metformin, sitagliptin

Analysis of the effect of seasonal administration on efficacy of sitagliptin: subanalysis of the JAMPstudy

February 15th 2018

This study suggested that the season of administration of sitagliptin influenced subsequent hypoglycemic effect even after analysis excluding the influence of HbA1c value at the start of treatment. This study provides possibility, indicating that seasonal fluctuations have an effect on the efficacy of antidiabetic drugs (Journal of Diabetes Investigation)

Categories: Medication, News
Tags: seasonal, sitagliptin

Categories: Medication
Tags: seasonal, sitagliptin

Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S)

September 21st 2017

The present pilot trial suggests that treatment of SPIDDM/LADA by sitagliptin, a DPP-4 inhibitor, may be more effective in preserving the β-cell function than insulin treatment for at least 4 years, possibly through the immune modulatory effects of DPP-4 inhibitors (Diabetes Therapy)

Categories: Medication, News
Tags: DPP-4 inhibitors, sitagliptin, Type 1 Diabetes

Categories: Medication
Tags: DPP-4 inhibitors, sitagliptin, Type 1 Diabetes

Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study

May 11th 2017

Adding sitagliptin to conventional antidiabetic regimens in patients with T2DM for 24 months attenuated the annual exacerbation in the echocardiographic parameter of diastolic dysfunction (E/e′) independent of other clinical variables such as blood pressure and glycemic control (Cardiovascular Diabetology)

Categories: Cardiovascular, News
Tags: sitagliptin, Type 2 Diabetes

Categories: Cardiovascular
Tags: sitagliptin, Type 2 Diabetes

Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: the DURATION-NEO-2 randomized clinical study

February 16th 2017

This study demonstrated that exenatide QWS-AI reduced HbA1c more than sitagliptin or placebo and was well tolerated (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: exenatide, metformin, sitagliptin, Type 2 Diabetes

Categories: Medication
Tags: exenatide, metformin, sitagliptin, Type 2 Diabetes

Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial

December 28th 2016

A 12-week treatment with liraglutide or sitagliptin only resulted in a brief and modest increase of plasma pancreatic enzyme concentrations in patients with type 2 diabetes. Apart from a minimal sitagliptin-induced increase in intraduodenal fluid secretion, pancreatic exocrine function was unaffected (Diabetes Care)

Categories: Medication, News
Tags: liraglutide, Pancreas, sitagliptin, Type 2 Diabetes

Categories: Medication
Tags: liraglutide, Pancreas, sitagliptin, Type 2 Diabetes

Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs

December 2nd 2016

Sitagliptin improved the HbA1c level and rate of achieving the target control levels in patients with type 2 diabetes mellitus who were previously untreated with, or poorly responsive to, existing antidiabetic drugs. Thus, sitagliptin is expected to be useful in this patient group (BMC Endocrine Disorders)

Categories: Medication, News
Tags: sitagliptin, Type 2 Diabetes

Categories: Medication
Tags: sitagliptin, Type 2 Diabetes

Adherence, persistence, and treatment discontinuation with sitagliptin compared to sulfonylureas as add-ons to metformin

August 18th 2016

SITA (vs. SU) + MET users had significantly higher mean PDC, adherence, and persistence. These trends were robust to model alterations and were more marked when accommodating OPEs  (Journal of Diabetes)

Categories: Medication, News
Tags: sitagliptin, sulfonylureas

Categories: Medication
Tags: sitagliptin, sulfonylureas

Urinary albumin excretion with sitagliptin compared to sulfonylurea as add on to metformin in type 2 diabetes patients with albuminuria: a real-world evidence study

May 18th 2016

Our results suggest that both sitagliptin and SU reduce albuminuria as an add-on therapy to metformin, but that sitagliptin may provide greater reductions in albuminuria independent of glycemic control when compared to SU. Larger population studies are required to further explore this (Diabetes and Its Complications)

Categories: Nephrology, News
Tags: albuminuria, sitagliptin, sulfonylureas, Type 2 Diabetes

Categories: Nephrology
Tags: albuminuria, sitagliptin, sulfonylureas, Type 2 Diabetes

Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs

April 26th 2016

In this large cohort study, a higher risk for hHF was not observed in users of saxagliptin or sitagliptin compared with other selected antihyperglycemic agents (Annals of Internal Medicine)

Categories: Medication, News
Tags: saxagliptin, sitagliptin

Categories: Medication
Tags: saxagliptin, sitagliptin

Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus

April 14th 2016

Sitagliptin use does not affect the risk for hHF in T2DM, both overall and among high-risk patient subgroups (JAMA Cardiology)

Categories: Medication, News
Tags: heart failure, sitagliptin

Categories: Medication
Tags: heart failure, sitagliptin

Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus

March 23rd 2016

The treatment with DPP-4i: sitagliptin and vildagliptin provides favorable metabolic and vascular effects beyond glucose-control. Further studies are required to elucidate their implication in metabolic pathways (Diabetology & Metabolic Syndrome)

Categories: Medication, News
Tags: DPP-4 inhibitors, sitagliptin, Type 2 Diabetes, vildagliptin

Categories: Medication
Tags: DPP-4 inhibitors, sitagliptin, Type 2 Diabetes, vildagliptin

Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes

February 1st 2016

Sitagliptin attenuated the progression of carotid IMT in insulin-treated patients with T2DM free of apparent cardiovascular disease compared with conventional treatment (Diabetes Care)

Categories: Cardiovascular, News
Tags: carotid intima-media thickening, sitagliptin, Type 2 Diabetes

Categories: Cardiovascular
Tags: carotid intima-media thickening, sitagliptin, Type 2 Diabetes

Effects of sitagliptin on circulating zinc-α2-glycoprotein levels in newly diagnosed type 2 diabetes patients: a randomized trial

December 15th 2015

A low level of circulating ZAG is associated with insulin resistance and sitagliptin treatment significantly increases circulating ZAG levels. These observations have implications in relation to the mode of action of the DPP-IV inhibitor as an insulin sensitizing agent (European Journal of Endocrinology)

Categories: Medication, News
Tags: sitagliptin, Type 2 Diabetes, zinc-α2-glycoprotein

Categories: Medication
Tags: sitagliptin, Type 2 Diabetes, zinc-α2-glycoprotein

Reduction of serum concentration of FABP4 by sitagliptin in patients with type 2 diabetes mellitus

October 19th 2015

Sitagliptin decreases serum FABP4 level, at least in part, via reduction in the expression and consecutive secretion of FABP4 in adipocytes by direct inhibition of DPP-4

Categories: Medication, News
Tags: DPP4, FABP4, sitagliptin, Type 2 Diabetes

Categories: Medication
Tags: DPP4, FABP4, sitagliptin, Type 2 Diabetes

Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes

October 12th 2015

Treatment with sitagliptin for 12 weeks reduced the number of circulating CD4+ T cells, especially Th17 and Treg cells, in patients with type 2 diabetes (Diabetes Research and Clinical Practice)

Categories: Medication, News
Tags: CD4+ T cells, sitagliptin, Type 2 Diabetes

Categories: Medication
Tags: CD4+ T cells, sitagliptin, Type 2 Diabetes

Sitagliptin in type 2 diabetes mellitus: Efficacy after five years of therapy

September 3rd 2015

Sitagliptin seems to maintain its positive effects on glycemia and fasting plasma insulin on the long term (Pharmacological Research)

Categories: Medication, News
Tags: sitagliptin

Categories: Medication
Tags: sitagliptin

Distinct glucose-lowering properties in good responders treated with sitagliptin and alogliptin

August 4th 2015

These results implicate that the effects on diabetic parameters and the glucose-lowering mechanisms of these two drugs might be different in those who have good response with these drugs. Accordingly, the choice of these drugs may be dependent on the characteristics of the patients (International Journal of Clinical Practice)

Categories: Medication, News
Tags: alogliptin, sitagliptin

Categories: Medication
Tags: alogliptin, sitagliptin

Risk of new-onset heart failure in patients using sitagliptin: a population-based cohort study

July 24th 2015

In our sample of patients who are at high risk of heart failure after acute coronary syndrome, sitagliptin exposure was not associated with an increased risk of de novo heart failure (Diabetic Medicine)

Categories: Medication, News
Tags: heart failure, sitagliptin

Categories: Medication
Tags: heart failure, sitagliptin

Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study

July 7th 2015

HbA 1c was improved by 2 years of sitagliptin therapy in all three age groups, and age did not seem to influence the incidence of hypoglycemic events. These results confirm the efficacy and safety of sitagliptin in patients ≥ 75 years old, suggesting that it is also useful for treating elderly patients with T2DM (BMC Endocrine Disorders)

Categories: Medication, News
Tags: sitagliptin

Categories: Medication
Tags: sitagliptin
  • 1
  • 2
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Novo NordiskNapp DiabetesAstraZenecaMSD

Silver Sponsors

Abbott Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)AmgenSanofi Diabetes

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin cancer CGM closed-loop dapagliflozin DPP4 Empagliflozin Europe exenatide exercise GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis liraglutide metformin microvascular mortality NICE OGTT pioglitazone pregnancy retinopathy RYGB SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2019 Glycosmedia Partnership